Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

Diabetes Care

Volumn 35, Issue 5, 2012, Pages 1008-1014

  Mychaleckyj, Josyf C ^a   Craven, Timothy ^b   Nayak, Uma ^a   Buse, John ^c   Crouse, John R ^b   Elam, Marshall ^d   Kirchner, Kent ^e   Lorber, Daniel ^f   Marcovina, Santica ^g   Sivitz, William ^h   Sperl Hillen, Joann ⁱ   Bonds, Denise E ^j   Ginsberg, Henry N ^k  

^a UNIVERSITY OF VIRGINIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k Columbia University ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PLACEBO; SIMVASTATIN;

AGED; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

AGED; CREATININE; FENOFIBRATE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; MIDDLE AGED; RENAL INSUFFICIENCY;

EID: 84862076457     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1811     Document Type: Article

References (19)

1. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-1999
2. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001;55:39-44 (Pubitemid 32041781)
3. Boissonnat P, Salen P, Guidollet J, et al. The long-termeffects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994;58:245-247 (Pubitemid 24236221)
4. Rössner S, Orö L. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. Atherosclerosis 1981;38:273-282 (Pubitemid 11166889)
5. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-493 (Pubitemid 40341327)
6. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004;93:848-853 (Pubitemid 38429595)
7. Davis TM, Ting R, Best JD, et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-290
8. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
9. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002;92:536-541
10. Ansquer JC, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-913 (Pubitemid 351697561)
11. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001;358:39-40 (Pubitemid 32709742)
12. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010;33:215-220
13. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 1999;20:41-44 [in French] (Pubitemid 29091030)
14. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
15. GinsbergHN, Bonds DE, Lovato LC, et al.; ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:56i-67i
16. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
18. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
19. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406